MA40894A - Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production - Google Patents
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de productionInfo
- Publication number
- MA40894A MA40894A MA040894A MA40894A MA40894A MA 40894 A MA40894 A MA 40894A MA 040894 A MA040894 A MA 040894A MA 40894 A MA40894 A MA 40894A MA 40894 A MA40894 A MA 40894A
- Authority
- MA
- Morocco
- Prior art keywords
- lymphocytes
- target
- production processes
- heterodimeric immunoglobulins
- heterodimeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/073738 WO2015063339A1 (fr) | 2013-11-04 | 2014-11-04 | Production de cellules t reciblant des immunoglobulines héréro-dimériques |
| EP15167034 | 2015-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40894A true MA40894A (fr) | 2017-09-12 |
Family
ID=53059011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040894A MA40894A (fr) | 2014-11-04 | 2015-11-02 | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP3215541A1 (fr) |
| JP (3) | JP2018501297A (fr) |
| KR (1) | KR20170078831A (fr) |
| CN (1) | CN107207596A (fr) |
| AU (1) | AU2015341884B2 (fr) |
| BR (1) | BR112017009263A2 (fr) |
| CA (1) | CA2965745C (fr) |
| CL (1) | CL2017001090A1 (fr) |
| CO (1) | CO2017005240A2 (fr) |
| EA (1) | EA039658B1 (fr) |
| HK (1) | HK1244014A1 (fr) |
| IL (1) | IL251848A0 (fr) |
| MA (1) | MA40894A (fr) |
| MX (1) | MX2017005814A (fr) |
| MY (1) | MY186929A (fr) |
| NZ (1) | NZ732019A (fr) |
| PE (1) | PE20171041A1 (fr) |
| PH (1) | PH12017500819A1 (fr) |
| SG (1) | SG11201703313SA (fr) |
| WO (1) | WO2016071355A1 (fr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014205086B2 (en) | 2013-01-14 | 2019-04-18 | Xencor, Inc. | Novel heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US11161906B2 (en) | 2013-07-25 | 2021-11-02 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| CA2929256C (fr) | 2013-11-04 | 2022-04-26 | Glenmark Pharmaceuticals S.A. | Production de cellules t reciblant des immunoglobulines herero-dimeriques |
| RS59907B1 (sr) | 2014-03-28 | 2020-03-31 | Xencor Inc | Bispecifična antitela koja se vezuju za cd38 i cd3 |
| JP7020909B2 (ja) * | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| RS62332B1 (sr) | 2014-11-26 | 2021-10-29 | Xencor Inc | Heterodimerna antitela koja vezuju cd3 i cd20 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| CA2968878A1 (fr) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Anticorps heterodimeriques se liant aux antigenes cd3 et cd38 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EP3387013B1 (fr) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Anticorps hétérodimères se liant à cd3 et psma |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| US10787518B2 (en) | 2016-06-14 | 2020-09-29 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| WO2018005706A1 (fr) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Anticorps hétérodimériques qui se lient au récepteur 2 de la somatostatine |
| CA3060190A1 (fr) * | 2017-04-24 | 2018-11-01 | Glenmark Pharmaceuticals S.A. | Anticorps bispecifiques de redirection de lymphocytes t pour le traitement de cancers positifs de l'egfr |
| CN110691789A (zh) | 2017-06-05 | 2020-01-14 | 努玛治疗有限公司 | 新型抗cd3抗体 |
| WO2018224441A1 (fr) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Nouveaux anticorps anti-cd3 |
| EP3635002A1 (fr) * | 2017-06-08 | 2020-04-15 | Black Belt Therapeutics Limited | Anticorps permettant de moduler cd38 |
| CN117534754A (zh) | 2017-06-08 | 2024-02-09 | 黑带医疗有限公司 | Cd38调节抗体 |
| CA3070789A1 (fr) | 2017-08-10 | 2019-02-14 | Grifols Diagnostic Solutions Inc. | Compositions, procedes et/ou kits comprenant un domaine extracellulaire de cd38 humain recombinant |
| SG11202000484TA (en) | 2017-08-16 | 2020-02-27 | Black Belt Therapeutics Ltd | Cd38 antibody |
| WO2019035938A1 (fr) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| US11472889B2 (en) | 2017-10-14 | 2022-10-18 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| CN112955220A (zh) * | 2018-09-25 | 2021-06-11 | 伊克诺斯科学公司 | 生物样品中的抗体定量 |
| KR102353568B1 (ko) * | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편 |
| AU2020211728A1 (en) * | 2019-01-23 | 2021-08-12 | Encefa | CD31 competitors and uses thereof |
| WO2020182984A2 (fr) * | 2019-03-13 | 2020-09-17 | Ichnos Sciences SA | Glycosylation sans consensus d'anticorps bispécifiques |
| TW202110887A (zh) * | 2019-05-23 | 2021-03-16 | 美商維洛斯生物公司 | 抗ror1/抗cd3雙特異性結合分子 |
| WO2020250940A1 (fr) * | 2019-06-11 | 2020-12-17 | 小野薬品工業株式会社 | Agent d'immunosuppression |
| CN110551222B (zh) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | 一种新型双功能抗体及其用途 |
| EP4039707A4 (fr) * | 2019-09-30 | 2022-11-16 | Harbour Biomed (Shanghai) Co., Ltd | Anticorps de ciblage de cd3, anticorps bispécifique et son utilisation |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| CA3176391A1 (fr) * | 2020-04-24 | 2021-10-28 | Memorial Sloan-Kettering Cancer-Center | Anticorps anti-cd3 et utilisations associees |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| KR20230028386A (ko) * | 2020-06-17 | 2023-02-28 | 와이-맙스 테라퓨틱스 인코포레이티드 | 인간 질환의 치료를 위한 cd38 항체 |
| WO2022040482A1 (fr) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Compositions anti-cd28 et/ou anti-b7h3 |
| EP4305065A1 (fr) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Anticorps hétérodimères qui se lient au cd3 et au gpc3 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2511297B1 (fr) * | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anticorps humains anti-CD38 et leurs utilisations |
| EP3153525A1 (fr) * | 2005-03-23 | 2017-04-12 | Genmab A/S | Anticorps dirigés contre cd38 pour le traitement du myélome multiple |
| CA2625681C (fr) * | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain |
| EP1914242A1 (fr) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
| SI2975051T1 (sl) * | 2009-06-26 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom |
| BR112012017124C1 (pt) * | 2009-12-25 | 2021-08-31 | Chugai Pharmaceutical Co Ltd | Método para produzir e para purificar um multímero polipeptídico |
| EP2580243B1 (fr) * | 2010-06-09 | 2019-10-16 | Genmab A/S | Anticorps dirigés contre le cd38 humain |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CN108285488B (zh) * | 2011-03-25 | 2023-01-24 | 伊克诺斯科学公司 | 异二聚体免疫球蛋白 |
| AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| EP2914302B1 (fr) * | 2012-11-05 | 2017-01-04 | MorphoSys AG | Anticorps radiomarqué et ses utilisations |
| CA2929256C (fr) * | 2013-11-04 | 2022-04-26 | Glenmark Pharmaceuticals S.A. | Production de cellules t reciblant des immunoglobulines herero-dimeriques |
-
2015
- 2015-11-02 MA MA040894A patent/MA40894A/fr unknown
- 2015-11-03 SG SG11201703313SA patent/SG11201703313SA/en unknown
- 2015-11-03 JP JP2017542319A patent/JP2018501297A/ja active Pending
- 2015-11-03 AU AU2015341884A patent/AU2015341884B2/en active Active
- 2015-11-03 MX MX2017005814A patent/MX2017005814A/es unknown
- 2015-11-03 CA CA2965745A patent/CA2965745C/fr active Active
- 2015-11-03 PE PE2017000802A patent/PE20171041A1/es unknown
- 2015-11-03 WO PCT/EP2015/075628 patent/WO2016071355A1/fr active Application Filing
- 2015-11-03 MY MYPI2017701499A patent/MY186929A/en unknown
- 2015-11-03 KR KR1020177015252A patent/KR20170078831A/ko not_active Application Discontinuation
- 2015-11-03 CN CN201580072196.8A patent/CN107207596A/zh active Pending
- 2015-11-03 EP EP15790129.9A patent/EP3215541A1/fr not_active Withdrawn
- 2015-11-03 NZ NZ732019A patent/NZ732019A/en unknown
- 2015-11-03 BR BR112017009263-8A patent/BR112017009263A2/pt not_active Application Discontinuation
- 2015-11-03 EA EA201790961A patent/EA039658B1/ru unknown
-
2017
- 2017-04-23 IL IL251848A patent/IL251848A0/en unknown
- 2017-05-02 CL CL2017001090A patent/CL2017001090A1/es unknown
- 2017-05-03 PH PH12017500819A patent/PH12017500819A1/en unknown
- 2017-05-26 CO CONC2017/0005240A patent/CO2017005240A2/es unknown
-
2018
- 2018-03-12 HK HK18103440.0A patent/HK1244014A1/zh unknown
-
2019
- 2019-07-23 JP JP2019135318A patent/JP2019214582A/ja active Pending
-
2021
- 2021-08-02 JP JP2021126392A patent/JP7403505B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017001090A1 (es) | 2018-01-05 |
| CN107207596A (zh) | 2017-09-26 |
| CA2965745A1 (fr) | 2016-05-12 |
| AU2015341884A1 (en) | 2017-06-08 |
| EA039658B1 (ru) | 2022-02-22 |
| PH12017500819A1 (en) | 2017-10-02 |
| JP7403505B2 (ja) | 2023-12-22 |
| PE20171041A1 (es) | 2017-07-19 |
| EP3215541A1 (fr) | 2017-09-13 |
| HK1244014A1 (zh) | 2018-07-27 |
| IL251848A0 (en) | 2017-06-29 |
| SG11201703313SA (en) | 2017-05-30 |
| AU2015341884B2 (en) | 2020-09-17 |
| MY186929A (en) | 2021-08-26 |
| CA2965745C (fr) | 2023-12-05 |
| JP2019214582A (ja) | 2019-12-19 |
| CO2017005240A2 (es) | 2017-10-31 |
| WO2016071355A1 (fr) | 2016-05-12 |
| NZ732019A (en) | 2022-07-29 |
| EA201790961A1 (ru) | 2017-10-31 |
| JP2021184722A (ja) | 2021-12-09 |
| BR112017009263A2 (pt) | 2018-01-30 |
| MX2017005814A (es) | 2017-08-02 |
| JP2018501297A (ja) | 2018-01-18 |
| KR20170078831A (ko) | 2017-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40894A (fr) | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production | |
| IL252467A0 (en) | Heterodimeric antibodies that bind cd3 and cd38 | |
| HK1257164A1 (zh) | 新型抗pd-l1抗體 | |
| IL255727A (en) | Novel anti-pd-l1 antibodies | |
| HK1246324A1 (zh) | 抗pd-l1抗體 | |
| IL257062A (en) | New anti-pd-1 antibodies | |
| IL248007A0 (en) | Bispecific antibodies that bind to cd38 and cd3 | |
| MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| MA40889A (fr) | Immunoglobulines héréro-dimériques reciblant des lymphocytes | |
| PT3331910T (pt) | Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano | |
| SG10201603721TA (en) | Anti-CTLA-4 Antibodies | |
| HK1251055A1 (zh) | 用於結構化多字段文件布局的自動化解釋 | |
| RS62332B1 (sr) | Heterodimerna antitela koja vezuju cd3 i cd20 | |
| MA42829A (fr) | Compositions dérivées de placenta et procédés pour les produire | |
| MA41375A (fr) | Anticorps igg bispécifiques et leurs procédés de préparation | |
| IL247322A0 (en) | Antibodies to complement factor bb | |
| MA39915A (fr) | Composés de pladiénolide pyridine et leurs procédés d'utilisation | |
| IL247285A0 (en) | Monoclonal antibodies against the Marburg virus | |
| MA44517A (fr) | Compositions d'immunoglobuline intraveineuse recombinante (rivig) et leurs procédés de production et d'utilisation | |
| DK3250491T3 (en) | Product turner and placer | |
| MA45831A (fr) | Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation | |
| BR112017016027A2 (pt) | produto de padaria | |
| ZA201604024B (en) | Improved feeding strategies and purification processes for monoclonal antibody production | |
| DK3307076T3 (da) | Podepartikelprodukt | |
| GB201621446D0 (en) | IL-11 antibodies |